Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Thyroid Carcinoma, Anaplastic × efatutazone × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1 Neoplasms 1

Interventions

Cisplatin 2 tislelizumab 1 surufatinib 1 spartalizumab 1 sapanisertib 1 pegfilgrastim 1 fosbretabulin 1 efatutazone 1 crolibulin 1 Radiotherapy 1 Paclitaxel 1 Filgrastim 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Daiichi Sankyo

Phase 1/2 Terminated

19 enrolled 13 charts

EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡